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ABSTRACT
Mice lose 20% to 25% of trabecular bone mineral content (BMC) during lactation and restore it after weaning through unknown
mechanisms. We found that tibial Pthrp mRNA expression was upregulated fivefold by 7 days after weaning versus end of lactation in
wild-type (WT) mice. To determine whether parathyroid hormone–related protein (PTHrP) stimulates bone formation after weaning,
we studied a conditional knockout in which PTHrP is deleted from preosteoblasts and osteoblasts by collagen I promoter–driven
Cre (Cre
ColI). These mice are osteopenic as adults but have normal serum calcium, calcitriol, and parathyroid hormone (PTH). Pairs
of Pthrp
flox/flox;Cre
ColI (null) and WT;Cre
ColI (WT) females were mated and studied through pregnancy, lactation, and 3 weeks of
postweaning recovery. By end of lactation, both genotypes lost lumbar spine BMC: WT declined by 20.6% 3.3%, and null decreased by
22.5% 3.5% (p<.0001 versus baseline; p¼NS between genotypes). During postweaning recovery, both restored BMC to baseline: WT
to –3.6% 3.7% and null to 0.3% 3.7% (p¼NS versus baseline or between genotypes). Similar loss and full recovery of BMC were seen
atthewholebodyandhindlimb.Histomorphometryconfirmedthatnullshadlowerbonemassatbaselineandthatthiswasequaltothe
value achieved after weaning. Osteocalcin, propeptide of type 1 collagen (P1NP), and deoxypyridinoline increased equally during
recovery in WT and null mice; PTH decreased and calcitriol increased equally; serum calcium was unchanged. Urine calcium increased
during recovery but remained no different between genotypes. Although osteoblast-derived PTHrP is required to maintain adult bone
mass and Pthrp mRNA upregulates in bone after weaning, it is not required for recovery of bone mass after lactation. The factors that
stimulate postweaning bone formation remain unknown.  2011 American Society for Bone and Mineral Research.
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Introduction
S
ubstantial amounts of calcium are rapidly supplied to
lactating mammary tissue to produce calcium-rich milk.
Several lines of evidence have shown that mammals meet this
demand by resorbing bone and reducing bone mineral content
(BMC) during lactation irrespective of dietary calcium intake.
(1–3)
The lactational losses are greater from trabecular than cortical
bone and from the spine compared with the appendicular
skeleton.
(1–3) Within 2 to 6 months of exclusive lactation, women
typically lose 5% to 10% of BMC, whereas teenaged mothers and
women lactating twins may lose even more.
(1,4) In contrast to
humans, lactating rodents are faced with a proportionately
greater calcium demand from litters of 6 to 12 pups and will lose
20% to 25% of BMC during 3 weeks of lactation (and even more
with larger litters or dietary calcium restriction).
(1,5–7) The skeletal
losses reach 55% of trabecular BMC in mice that lack the gene
encoding calcitonin and calcitonin gene–related peptide a.
(6)
The mechanism by which these lactation-induced losses of
skeletal mineral content occur has been the subject of recent
investigations by our laboratories.
(6–12) The mammary glands
produce large amounts of parathyroid hormone–related protein
(PTHrP). PTHrP is secreted at high concentrations into milk, but
some escapes into the maternal circulation with suckling, where
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1242it has an impact on systemic mineral homeostasis. Together with
low estradiol, PTHrP acts to stimulate osteoclast-mediated bone
resorption,
(13) and additional stimulatory factors may be
implied.
(14) It also has been appreciated more recently that
osteocytic osteolysis occurs during lactation and likely con-
tributes to the loss of mineral content.
(15)
At the end of lactation, osteoclasts undergo apoptosis, and
osteoblasts begin to rapidly build bone and remineralize the
skeleton.
(1,16) Osteocytic lacunae also show tetracycline labeling,
confirming that new bone is being laid down at these sites.
(17,18)
Typically within 6 months in humans and 2 to 3 weeks in mice,
the BMC returns to the prepregnancy baseline value,
(1–3) even in
mice that have lost 55% of spine BMC.
(6) This means that the
postweaning skeleton gains 2% to 3% BMC per month in
humans and 10% to 20% per week in mice. This rapid pace of
bone formation is unparalleled at any other time in adult life;
losses owing to inactivity, estrogen deprivation, systemic illness,
corticosteroid treatment, and weightlessness or bed rest are
slowly and incompletely restored.
(1,19–24) The completeness of
skeletal recovery has been confirmed by epidemiologic studies
of young and postmenopausal women that found no adverse
effect of lactation on bone mass, bone density, or hip fracture
risk; in several studies, lactation conferred a higher bone mass
and lower risk of osteoporosis.
(1,25,26)
What is especially puzzling and most clinically relevant is that
the factors that stimulate bone formation after weaning are
unknown.Repletionofovarian hormonesislikelyafactorbutnot
the sole explanation, especially because reproductive-age
women who have undergone 6 months of estrogen deprivation
therapyloseatrivialamountofBMCbutstillhaveadeficitinBMC
a year after return of normal ovarian function.
(1) We have studied
the role of the classic calciotropic hormones and found that mice
lacking parathyroid hormone (PTH), calcitonin, or the vitamin D
receptor (VDR) are able to stimulate bone formation after
weaning and fully restore BMC that was lost during lacta-
tion.
(6,7,12)
Sustained high levels of PTH (eg, primary or secondary
hyperparathyroidism) and PTHrP (eg, hypercalcemia of malig-
nancy, mammary hyperplasia, and normal lactation) are well
known to stimulate bone resorption.
(27,28) Conversely, short
pulses of PTH or PTHrP (such as through the use of once-daily
subcutaneous injections) have been shown to stimulate bone
formation in humans and rodents, both PTH(1–34) (teriparatide)
and PTH(1–84) are clinically approved anabolic treatments for
osteoporosis, and PTHrP(1–36) is currently being studied for the
same purpose.
(29,30) PTH and PTHrP stimulate bone formation by
actingonthePTH/PTHrP receptorexpressed byosteoblasts.
(27,28)
Sustained high levels of PTH or PTHrP upregulate osteoblast
expression of the receptor activator of NF-kB ligand (RANKL) and
downregulate their expression of osteoprotegerin (OPG); the
result is stimulation of osteoclast differentiation, osteoclast
function, and bone resorption.
(31)
The ability of PTH and PTHrP to stimulate bone formation
makes them obvious candidates to stimulate bone formation
during postweaning recovery. And yet our studies of mice
lacking PTH have shown no impairment in the ability of such
mice to recover from skeletal losses during lactation.
(12)
Although mammary-derived PTHrP contributes to the skeletal
losses during lactation, this tissue source cannot explain
postweaning skeletal recovery because the mammary glands
rapidly involute after weaning, and plasma PTHrP levels normally
are low or undetectable except during lactation in humans and
rodents.
(1,2)
Another relevant source of PTHrP in the adult skeleton is
preosteoblasts and osteoblasts.
(32) Recent studies have shown
that PTHrP, in particular osteoblast-derived PTHrP, contributes to
the maintenance of adult bone mass
(32–34); without it, mice
lacking osteoblast-derived PTHrP (obPthrp nulls) have signifi-
cantly reduced bone mass and strength.
(32)
We hypothesized that PTHrP is upregulated in bone during
postweaning to stimulate bone formation and skeletal recovery,
and we used obPthrp null mice to test this hypothesis.
Materials and Methods
Animal husbandry
Aprevious report has described in detail how the Pthrp gene was
deleted using Cre-lox technology and the collagen I promoter to
drive the Cre recombinase.
(32) These obPthrp mice were
backcrossed into the parent strain, C57BL/6, for more than 10
generations and maintained by breeding heterozygous-deleted
mice together. Mice were genotyped from DNA extracted from
tail clips of newly weaned pups. A Southern blot detected the
floxed and normal Pthrp allele, whereas polymerase chain
reaction (PCR) was used to detect the presence of the Cre
recombinase; the probes, primers, and conditions have been
reported previously.
(32,35)
Reproductive studies compared Pthrp
flox/flox;Cre
ColI (obPthrp
null) mice with Pthrp
þ/þ;Cre
ColI (control or wild-type) mice. To
obtain these, Pthrp
flox/þ;Cre
ColI (heterozygous) mice were mated
together, and offspring not expressing Cre were discarded. The
heterozygotes contributed to maintaining the colony, whereas
the wild-type (WT) and obPthrp null mice were used in
experiments.
Experimental mice were mated overnight. The presence of a
vaginal mucus plug on the morning after mating marked
gestational day 0.5; normal gestation is 19 days. The mice had
ad libitum access to water and a standard rodent diet containing
1% calcium. All studies were performed with the prior approval
of the respective investigator’s animal ethics committee
(Institutional Animal Care Committee of Memorial University
of Newfoundland and the Institutional Animal Care and Use
Committee at Yale University).
Reproductive cycles and data-collection time points
In the studies to determine PTHrP expression in bone during
recovery from lactation, weaning was forced at day 12 of
lactation by removing the pups from the mother. The remaining
studies were completed according to approximate 75-day
reproductive cycles. A minimum of two baseline BMC scans
and blood/urine collections were completed over 5 to 10 days
prior to first mating (prepregnancy interval). Additional BMC
scans and sample collections also were done on day 18.5 of
pregnancy, day 21 of lactation (39.5 days after the start of
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skeleton (days 7, 14, and 21 after weaning). Consequently, the
mice had an expected mean age of 23 weeks by the end of
postweaning recovery.
Bone mineral content
We measured BMC with the PIXImus 2 Bone Densitometer (GE
Lunar, Madison, WI, USA), calibrated daily to a standard phantom
(fat 11.9% and BMC 0.063g). Data were analyzed with PIXImus
software (Version 2.1). Anesthesia was induced with isoflurane
(Baxter, Mississauga, ON, Canada) and maintained for 5 to
15minutes with a single intraperitoneal injection of a 5:1
combination of ketamine hydrochloride (Wyeth Animal Health,
Guelph, ON, Canada) and xylazine (Bayer, Toronto, ON, Canada).
The anesthetized mice were immobilized prone on holding trays
with the spine straightened; to maintain reproducibility with less
than 0.5% precision error, the head was excluded in all scans. In
prior quality-control studies,mice onday18.5 ofpregnancy were
scanned immediately before and after the pups were removed
byC-section;thisdeterminedthatthefetalskeletonscontributed
less than 1% to the apparent maternal BMC and therefore were
negligible.
(6,36) Whole-body and regional (ie, spine and hind
limb) BMC measurements were obtained for each mouse, and
the absolute values were normalized to the respective
nonpregnant baseline measurements.
Chemical and hormone assays
Urine and sera were collected in the morning by having mice
voidintoaclean,emptycage;afterthis,bloodwastakenfromtail
veins. Serum or urine calcium, phosphorus, and creatinine were
measured with colorimetric assays (Diagnostic Chemicals
Limited, Charlottetown, PEI, Canada). PTH was measured with
a rodent PTH(1–34) ELISA kit that has a detection limit of 1.6pg/
mL (Immutopics, San Clemente, CA, USA). Calcitriol was analyzed
with an EIA kit with a detection limit of 6pmol/L (Immuno-
diagnostic Systems, Ltd., Boldon, Tyne and Wear, UK). Bone
markers included osteocalcin, assessed by a two-site immunor-
adiometric assay (Immutopics); propeptide of type 1 collagen
(P1NP) by EIA (Immunodiagnostic Systems); and deoxypyridino-
line, assessed by the METRA DPD enzyme immunoassay kit
(QuidelCorporation,SanDiego,CA,USA).Urinarydeoxypyridino-
line, calcium, and phosphorus were expressed relative to
creatinine to correct for variations in urine concentration.
Biomechanical testing
Tibias were harvested on day 7 after weaning (during rapid bone
recovery), stripped of soft tissues, and stored at  208C. They
were thawed to room temperature in PBS for at least 2hours
prior to analysis. Cortical bone strength was assayed using a
single-column Instron Series 3340 electromechanical test
instrument (Instron, Norwood, MA, USA). In brief, each tibia
was immobilized at each end in a fixture, and a load cell with
maximum capacity of 10N of force was positioned 1cm above
the tibial midshaft. The load cell’s cross-head descended at
10mm/minute. The force required to break the tibia (failure) and
other biomechanical parameters were detected and recorded
automatically by computer.
RNA extraction
Baseline expression of PTHrP in WT bone was determined in
tibias harvested on day 12 of lactation (day of forced weaning)
and days 1, 3 and 7 of postweaning recovery. Additional tibias
from obPthrp null mice and WT siblings were obtained on day 7
of postweaning recovery following a normal 21-day lactation.
The growth plates were removed to eliminate cartilaginous
tissue. The tibias were snap frozen in liquid nitrogen. Total RNA
was extracted and purified using the RNeasy Midi Kit (Qiagen,
Valencia, CA, USA). RNA quality was confirmed with the Agilent
2100 BioAnalyzer (Agilent Technologies, Santa Clara, CA, USA).
Real-time quantitative RT-PCR
We used TaqMan gene expression assays to determine
expression of PTHrP in bones with predesigned primers and
probes for optimal amplification. Details of conditions and cycle
times have been reported previously.
(6,37) We used the TaqMan
RNA-to-CT 1-Step Kit (Applied Biosystems, Inc., Foster City, CA) in
addition to the TaqMan gene expression assays in order to
eliminate the need to carry out a separate cDNA synthesis step
prior to real-time quantitative RT-PCR. With use of the TaqMan
RNA-to-CT 1-Step Kit, the thermal cycler protocol then consisted
of a 15-minute cycle at 488C, a 10-minute cycle at 958C, followed
by 40 cycles of 15seconds at 958C and 1 minute at 608C. We
performed all real-time quantitative RT-PCR using the ABI PRISM
7000 Sequence Detection System (Applied Biosystems), as
described previously.
(37,38) Allsampleswereanalyzedintriplicate
and in three separate experiments. Relative expression ratios
were representative of the threshold cycle (the PCR cycle at
which an increase in reporter fluorescence is above a baseline
signal) normalized to glyceraldehyde 3-phosphate dehydrogenase
(GAPDH) mRNA.
Histomorphometry
Tibias were obtained on day 21 of postweaning recovery,
stripped of muscle and other soft tissues, fixed in 10% buffered
formalin, and embedded in methacrylate. Histomorphometric
analysis of 5-mm toluidine blue-stained sections was carried out
across the width of the secondary spongiosa beginning 370mm
below the growth plate and extending for 1.11mm, as described
previously, using the Osteomeasure system (Osteometrics,
Decatur, GA, USA).
(7,39,40)
Statistical analysis
Data were analyzed using SYSTAT 5.2.1 for Macintosh (SYSTAT,
Inc, Evanston, IL, USA). ANOVA was used for the initial analysis;
Tukey’s test determined which pairs of means differed
significantly from each other. Real-time PCR results were
analyzed by the 2
–DDCT method, where the target and reference
are amplified in separate wells.
(41) Two-tailed probabilities are
reported, and all data are presented as mean SE.
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PTHrP is upregulated in bone during weaning
We forced weaning in WT mice on day 12 of lactation and
obtained their tibias during postweaning in order to assay Pthrp
mRNA expression by real-time quantitative RT-PCR. Pthrp mRNA
expression was similar on day 12 of lactation and the first day
after weaning but increased over fivefold by day 7 (Fig. 1). PTHrP
is expressed primarily by osteoblasts within bone,
(32) and so the
increased signal likely was coming from these cells. These results
indicate that PTHrP is upregulated in bone during postweaning
recovery.
Bone mineral content excursion in obPthrp null mice
TheupregulationofPTHrPinboneafterweaningindicatedthatit
may stimulate bone formation during this time frame. In
addition, prior studies in Pthrp
þ/– mice and in obPthrp null mice
indicated that osteoblast-derived PTHrP plays a physiologically
important role in regulating bone formation and adult bone
mass.
(32–34) Without osteoblast-derived PTHrP, baseline bone
mass and strength are reduced in adult mice.
(32) We therefore
studied obPthrp null mice during full reproductive cycles to
determineiflackofosteoblast-derivedPTHrPimpairedtheability
to stimulate bone formation and recover BMC after weaning.
Prior published work had shown that PTHrP expression is absent
in osteoblasts and preosteoblasts of obPthrp nulls.
(32) We
extracted RNA from tibias (with marrow intact) of obPthrp null
mice on day 7 of postweaning recovery and found that PTHrP
expression was undetectable through 35 cycles of quantitative
real-time RT-PCR; relative expression of Pthrp mRNA was
0.12 0.01 in obPthrp null versus WT mice (p<.0001). This
indicates not only that PTHrP was eliminated from bone but also
that normal expression in marrow is negligible at best.
We next determined changes in BMC in obPthrp null mice and
WT siblings throughout complete reproductive cycles. At
baseline, the whole-body BMC was numerically but not
significantly lower in obPthrp null mice than in their WT siblings
(0.487 0.008g versus 0.500 0.010g, p¼NS). There also was
no difference in baseline spine or hind limb BMC (data not
shown). These results are similar to the prior published report of
obPthrpnullmiceinwhichthearealbonemineraldensity(aBMD)
was slightly reduced but a more marked reduction in bone mass
was evident by micro–computed tomography (mCT) or histo-
morphometry.
(32) By the end of lactation, WT siblings and
obPthrp null mice lost the same amount ofwhole-body BMC, and
each recovered fully after weaning to a value not significantly
different from their respective baselines (Fig. 2A). The speed of
recovery to baseline was no different between control and
obPthrp null mice: Recovery was to  7.8% 2.1% and
 4.2% 2.2% of baseline in WT mice at 1 and 2 weeks after
weaning and  4.8% 2.4% and  2.1% 2.4% of baseline at the
respective time points in obPthrp null mice. The values plotted in
Fig. 2A were obtained at 3 weeks after weaning.
Skeletal losses are more profound from trabecular bone than
from cortical bone during lactation; whole-body BMC largely
reflects cortical bone, whereas the spine reflects largely
trabecular bone. WT and obPthrp null mice lost the same
amount of BMC from the spine by the end of lactation, and each
recovered fully after weaning with no differences between the
two (Fig. 2B). Notably, both WT and obPthrp null mice lost BMC
from the spine during pregnancy. This contrasts with our
previous reports of significant gains in BMC during pregnancy in
an outbred strain ofmice, Black Swiss (Taconic, Germantown, NY,
USA).
(6,7,36) At the hind limbs of WT and obPthrp null mice, there
were significant increases in BMC during pregnancy, in keeping
with the increased weight bearing. Losses at the hind limb
during lactation typically are less than at the spine or whole
body, and again there was no difference between WT and
obPthrp null mice, with full recovery observed in each after
weaning (Fig. 2C).
Static histomorphometry of the tibia confirmed that the
obPthrp null mice had lower trabecular bone volume and
trabecular number at baseline than WT mice (Table 1).
Interestingly, while trabecular bone volume in WT mice was
lower 21 days after weaning than baseline bone volume, in the
obPthrp null mice, bone volume was no different from baseline
after 21 days of recovery. There also were no significant
differences in osteoblast, osteoid, and osteoclast parameters
between genotypes or time points, although the low volume of
trabecular bone present in the mice may have limited the ability
to detect any differences (Table 1). The lower trabecular bone
volumeintibiasofpostweaningWTmicecontrastswiththedual-
energy X-ray absorptiometry (DXA) result and suggests that full
recovery of tibial microarchitecture did not occur. This is
consistent with a recent report that found regional differences in
the completeness of recovery of skeletal microarchitecture after
weaning, as determined by mCT: Spine recovered fully, whereas
femur and tibia had incomplete recovery, but at all three sites,
biomechanical strength returned to baseline.
(42)
Fig. 1. Pthrp mRNA expression is upregulated in bone during postwean-
ing recovery. Weaning was forced on day 12 of lactation, and skeletal
mRNA was analyzed by real-time quantitative RT-PCR. PTHrP expression
increased more than fivefold in bone through the first 7 days after
weaning. Values were normalized to GAPDH and then expressed relative
to the value on day 12 of lactation.
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during lactation and after weaning, there also was no difference
in bone turnover markers. Osteocalcin, P1NP, and deoxypyr-
idinoline rose significantly during postweaning compared with
baseline, but there was no difference between groups (Fig. 3).
Importantly, the rise in osteocalcin and P1NP during postwean-
ing is consistent with bone formation that occurs during this
interval. Of note is that deoxypyridinoline normally peaks in the
first 7 to 10 days of lactation during the interval of greatest bone
resorption, but this time point was not measured because the
focus inthis studywasonrecovery from lactation.Thetime point
shown in Fig. 3 is the end of lactation, by which point in time
bone resorption has lessened greatly.
Mineral metabolism during lactation and recovery
We also studied aspects of systemic mineral metabolism during
lactation and after weaning to determine if absence of
osteoblast-derived PTHrP impaired maternal mineral metabo-
lism or resulted in any compensatory responses. Serum calcium
and phosphorus remained unchanged (Table 2). Serum PTH
normally falls during lactation and remains low during
postweaning recovery, and this is what we observed in obPthrp
null and WT mice (Fig. 4A). Calcitriol showed the expected
marked increase during pregnancy and declined significantly
during recovery but still remained above baseline with no
differences between genotypes (Fig. 4B). Urine calcium typically
rises during pregnancy owing to increased intestinal calcium
absorption (absorptive hypercalciuria) and falls during lactation
to prepregnancy values or below. We observed the expected
significant decline in urine calcium during lactation, and at all
time points WT and obPthrp null mice showedsimilar values with
no significant differences between them (Fig. 5A). Urine
phosphorus increases significantly during lactation as a
consequence of accelerated bone resorption and possibly
PTHrP-stimulated phosphaturia, and this was found in obPthrp
null and WT mice with no differences between them (Fig. 5B).
Biomechanical testing
The obPthrpnull micehavebeen shown previouslytohave lower
bonemassthanWTmiceatbaseline,
(32)andthiscanbeexpected
to increase skeletal fragility. We harvested tibias at baseline and
day 7 of postweaning recovery, and we subjected those tibias to
the three-point bend test to failure. The tibias of WT and obPthrp
null mice were not weakened by lactation but absorbed more
energy prior to failure when obtained after weaning compared
with baseline (Table 3). Tibias from obPthrp null mice appeared
modestly weaker than those of WT mice at baseline and during
postweaning recovery, although the difference was only
significant on day 7 of postweaning recovery (Table 3).
Discussion
Enhanced skeletal resorption during lactation is a physiologically
important adaptation that enables the mother to provide the
necessary amount of calcium to milk. Moreover, this temporary
loss of bone mass can have adverse consequences in the short
term. A 5% to 10% loss of BMC over 2 to 6 months in humans can
Fig. 2. obPthrp null and WT mice experience identical changes in BMC
during pregnancy and lactation and after weaning. Relative changes in
whole-body (A), spine (B), and hind limb (C) BMC versus baseline are
depicted on day 18.5 of pregnancy, day 21 of lactation, and day 21 of
postweaning recovery. The number of observations is indicated in
parentheses.
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on the baseline BMC. Some lactating women present with
vertebral crush fractures and a very low BMC that was apparently
caused by skeletal losses during lactation.
(2) In rodents, the BMC
losses are more rapid and of greater magnitude than in humans,
with the most dramatic being a 55% loss of spine BMC observed
in mice that lack the gene encoding calcitonin and calcitonin
gene–related peptide a.
(6) In humans and all other mammals
that have been studied, the skeleton recovers bone mass during
postweaning, even in those who fractured
(43,44); consequently,
lactation is not associated with any long-term risk of skeletal
fragility or reduced bone mass.
(1,2)
While the mechanism by which skeletal resorption occurs
during lactation is reasonably but not fully elucidated, the
mechanisms that stimulate bone formation after weaning
remain unknown. The postweaning interval is a time of net
bone formation that is unequaled at any other time in the adult
human, but it bears similarity to comparable loss and recovery of
bone mass that occurs in egg-layers and animals that form
mineralized antlers and horns.
(1,3,45) Evidence described earlier
indicates that several classic calciotropic hormones (ie, PTH,
calcitriol/VDR, and calcitonin) are not required for the skeleton to
restore bone mass after weaning and that recovery of estradiol
levels to normal cannot explain the speed or completeness of
recovery either. In this study we add to this list by showing that
PTHrP is also not required.
Osteoblast-derived PTHrP is necessary for maintenance of
normal bone mass because obPthrp null mice have low bone
mass compared with their WT siblings.
(32) This prompted us to
consider whether osteoblast-derived PTHrP might stimulate
skeletal recovery after weaning. We found that Pthrp mRNA was
upregulated in bone during the postweaning interval, so we
used obPthrp null mice to determine if lack of osteoblast-derived
PTHrP impaired skeletal recovery after weaning. To our surprise,
we discovered that obPthrp null mice lactated normally, lost
the same amount of BMC as WT mice, and returned to baseline
BMC after weaning with no impairment in the magnitude or
speed of skeletal recovery. We also found no impact of the
absence of osteoblast-derived PTHrP on maternal mineral
homeostasis during prepregnancy, lactation, and postweaning.
PTH remained suppressed from prepregnancy baseline during
pregnancy, lactation, and postweaning recovery, indicating that
PTH did not need to upregulate in response to the absence of
PTHrP. Calcitriol increased normally during pregnancy and
postweaningwithnodifferencebetweengenotypes.Wedidfind
that obPthrp null mice had reduced trabecular bone volume and
strength in the tibias compared with WT siblings, thus
reaffirming that PTHrP is needed to maintain adult bone mass
and strength.
An important strength of our analytic approach is that sister
pairs of WT and obPthrp null mice were followed longitudinally
by densitometry through 75-day (or longer) reproductive cycles.
Consequently, the seven pairs of mice studied at the end of
recovery are represented at every time point of Fig. 2 and clearly
demonstrate loss of BMC from the whole body, spine, and hind
limb, with full recovery after weaning. So too the biochemical
analyses represent serial or longitudinal comparisons from mice
that contributed to all time points. In contrast, histomorpho-
metry and biomechanical testing are cross-sectional analyses
because mice must be euthanized at each time point. The
biomechanical testing showed no reduction in tibial strength of
either genotype after weaning, whereas the histomorphometric
analysis found incomplete recovery of tibial microarchitecture in
the WT mice. This is consistent with a recent mCT analysis of
normalmicethatdemonstrated incompleterecovery oftibiaand
femur but full recovery of spine microarchitecture after weaning
and full recovery of biomechanical strength at all three sites.
(42)
Our results indicate that osteoblast-derived PTHrP is not
responsible for the increase in bone mass that occurs after
lactation. It is conceivable that PTHrP still plays a role but that we
did not detect a compensatory mechanism that was invoked in
its absence. However, since the skeletal losses by the end of
lactation in mice are quite large ( 20% of spine BMC in this
study) and both genotypes restored this fully within the same
postweaning time frame, it seems more likely that PTHrP does
not play a significant role in this recovery. Instead, other factors
that remain to be elucidated must stimulate bone formation
after weaning.
Although we demonstrated that PTHrP expression is upregu-
latedinboneduringpostweaningrecoveryandthatthisincrease
is obliterated when PTHrP is eliminated from osteoblasts, it
remains unclear what role (if any) PTHrP might have in
Table 1. Static Histomorphometry of the Tibia at Baseline (12 Weeks of Age) and End of Recovery (Day 21 After Weaning or 23 Weeks of
Age)
Trabecular structure Osteoblast parameters Osteoclast parameters
Genotype BV/TV Tb.Th Tb.N OS/BS Ob.S/BS O.Th N.Ob/BPm OcS/BS N.Oc/BPm
(n)% mm /mm % % mm /mm % /mm
WT baseline (3) 3.9 0.5
a,b 22.1 2.8 1.7 0.2
a,b 13.3 1.6 14.9 2.0 0.41 0.05 12.1 0.6 4.9 1.5 2.7 0.6
WT recovery (6) 0.7 0.3
b 12.1 4.5 0.3 0.1
b 26.0 4.5 27.7 4.3 0.70 0.17 20.0 3.9 4.4 2.0 2.3 1.0
obPthrp null baseline (3) 0.9 0.4
a 17.8 0.3 0.8 0.1
a 17.3 8.6 18.8 8.9 0.35 0.05 11.9 6.5 4.8 0.4 2.9 0.4
obPthrp null recovery (5) 1.4 0.2 16.1 4.1 0.4 0.2 11.4 1.2 12.6 1.9 0.32 0.08 8.0 1.1 2.8 1.5 1.9 1.0
Abbreviations: BV/TV¼trabecular bone volume/total volume; Tb.Th¼trabecular thickness; Tb.N¼trabecular number; OS/BS¼osteoid surface/bone
surface; Ob.S/BS¼osteoblast surface/bone surface, O.Th¼osteoid thickness; N.Ob/BPm¼number of osteoblasts per unit bone perimeter; OcS/
BS¼osteoclast surface/bone surface; N.Oc/BPm¼number of osteoclasts per unit bone perimeter.
ap<.05 WT versus obPthrp null at same time point.
bp<.01 WT at baseline versus recovery.
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number alone does not explain this increase in total PTHrP
expression within bone. Inseparate analyses, wehave found that
osteoblast numbers at most double in WT mice by day 7 of
postweaning recovery (and osteoclast numbers decrease more
than 60%),
(46,47) whereas in this study we found that PTHrP is
upregulated fivefold in WT bone. Also, histomorphometric
assessment of rats found a similar doubling of osteoblast
numbers over the first 7 days after weaning, accompanied by an
80% decrease in osteoclast numbers.
(16,48)
It is notable that during pregnancy, WT and obPthrp null mice
had no significant change in whole-body BMC but lost a
significant amount from the spine and then lost even more
during lactation. This pattern differs from what we have reported
previously in the outbred Black Swiss strain, in which a 10% to
15% increase in BMC occurs at the whole body and little or no
change in BMC at the spine. The WT and obPthrp null mice were
in the C57BL/6 inbred strain, and this may explain why the
excursion in BMC differed across these reproductive time points.
This finding underscores that multiple genetic factors are likely
involved in regulating bone mass and resorption in response to
the demands of pregnancy and lactation. Black Swiss mice gain
significant BMC in advance of the demands of lactation, whereas
C57BL/6 mice lose BMC during pregnancy; both experience a
similar net loss of about 20% of BMC by the end of lactation.
Black Swiss micealso maintain ahigher ionizedcalcium andBMC
than C57BL/6 mice,
(6,7,49) so these two strains of mice may differ
withrespecttooneormoreunknowngenesthatarepertinentto
calcium and bone homeostasis.
Overall, the results of this study of obPthrp null mice have
yielded the important finding that PTHrP is not required for
skeletal recovery after lactation. Taken together with our
previous studies in PTH, VDR, and calcitonin/calcitonin gene–
related peptide a knockout mice, these results emphasize that
factors other than the known calciotropic hormones are
controlling the recovery of bone mass after lactation. Under-
standing how this interval of rapid and substantial bone
formation is regulated may lead to the discovery of novel
factors that stimulate bone formation and that might be
exploited to treat disorders of low bone mass and skeletal
fragility pharmacologically. Moreover, the phenotypic differ-
Table 2. Serum Chemistries at End of Pregnancy and Lactation
and Day 7 After Weaning
Genotype
(n) Baseline Pregnancy Lactation Recovery
Serum calcium (mmol/L)
WT (5) 1.97 0.07 2.06 0.08 2.00 0.06 2.04 0.08
obPthrp
null (5)
1.87 0.11 1.98 0.05 1.99 0.12 2.00 0.06
Serum phosphorus (mmol/L)
WT (5) 3.07 0.49 2.62 0.26 2.48 0.10 2.93 0.11
obPthrp
null (5)
2.98 0.35 1.93 0.23 2.91 0.37 2.89 0.20
Note: No statistically significant differences were observed.
Fig. 3. Bone turnover is increased after weaning. The bone markers
osteocalcin (A), deoxypyridinoline (B), and P1NP (C) increased equally
in WT and obPthrp null mice during postweaning recovery compared
with the prepregnancy baseline. Depicted here are baseline, day 18.5 of
pregnancy, day 21 of lactation, and day 7 of postweaning recovery. The
most marked increase in bone resorption occurs during the first 10 days
of lactation, but the time point assayed here was day 21 of lactation,
when the pups were weaned. The number of observations is indicated in
parentheses.
1248 Journal of Bone and Mineral Research KIRBY ET AL.ences between Black Swiss and C57BL/6 strains of mice may hint
at important genetic differences that are important for the
regulation of calcium and bone metabolism.
In conclusion, PTHrP is upregulated in bone during post-
weaning skeletal recovery, and it is required to maintain adult
bone mass and strength. However, osteoblast-derived PTHrP is
not required for the skeleton to recover from 20% losses of BMC
induced by lactation. The longitudinal DXA measurements
definitively show loss of bone mass at cortical and trabecular
sites, with full recovery achieved after weaning at all sites. The
biochemical (ie, calcium, PTH, calcitriol, and bone markers),
biomechanical (ie, three-point bending test), and mRNA
expression data (fivefold upregulation of PTHrP in WT bone
that is eliminated in the obPthrp null) make very clear that loss of
osteoblast-derived PTHrP does not compromise the ability of the
skeleton to recover after weaning and that calcitriol or PTH do
not upregulate to compensate for loss of PTHrP. The factors that
regulate bone formation after weaning remain to be identified.
Fig. 5. Flux in urinary calcium and phosphorus during reproductive
cycles. (A) Urinary calcium normally increases during pregnancy and
decreases during lactation; the fall during lactation was statistically
significant. (B) Urinary phosphorus decreased nonsignificantly during
pregnancy but increased significantly during lactation as a consequence
of enhanced bone resorption and possibly PTHrP-stimulated phospha-
turia. In all panels, there were no significant differences between WT and
obPthrp null mice. Time points depicted are baseline, day 18.5 of
pregnancy, day 21 of lactation, and day 7 of postweaning recovery.
The number of observations is indicated in parentheses.
Fig. 4. Flux in PTH and calcitriol during reproductive cycles. (A) PTH
normally becomes suppressed during pregnancy and lactation but rises
to baseline during postweaning recovery. This pattern was noted in WT
and obPthrp null mice, although the changes were not statistically
significant. (B) Calcitriol tripled during pregnancy, as expected, and then
declined during recovery but remained double the baseline value. No
significant differences were seen between WT and obPthrp null mice.
Time points depicted are baseline, day 18.5 of pregnancy, day 21 of
lactation, and day 7 of postweaning recovery. The number of observa-
tions is indicated in parentheses.
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